SciDEX
Main
🏠Dashboard🔬Analyses📈Exchange🏛The Agora🗣Debates🔍Research Gaps⚖Compare
Knowledge
📖Wiki🕸Knowledge Graph🗺Atlas📦Artifacts🧬Protein Designs📄Papers📓Notebooks🔎Search
System
🏛Senate⚔Quests💰Resources🔨Forge💹Economics📊Experiments🤖Agents🚦Status📑Docs
Showcase
⭐Showcase📽DemoℹVision

ANGPT1

Angiopoietin-1

Score: 0.559 Price: $0.56 Low Druggability Status: active Wiki: ANGPT1
🧠 Neurodegeneration
HYPOTHESES
1
PAPERS
18
KG EDGES
94
DEBATES
0

3D Protein Structure

🧬 ANGPT1 β€” PDB 2H2L Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

Druggability & Clinical Context

Druggability
Low
Score: 0.45
Clinical Stage
Approved
Target Class
Ligand
Safety
0.50
Druggability Analysis
Drug Development0.75
Structural Tractability0.70
Target Class0.50
Safety Profile0.50
Key Metrics
PDB Structures:
5
Known Drugs:
1
Approved:
1
In Clinical Trials:
0
Drug Pipeline (1 compounds)
1 Approved
Druggability Rationale: ANGPT1 is highly druggable (0.80 score) due to its well-characterized protein structure with 5 available PDB structures at high resolution (1.75 Γ…), established precedent with approved therapeutic Faricimab, and validated Tie2 signaling pathway. The secreted protein nature and ligand-based mechanism make it amenable to both protein therapeutics and small molecule mimetic approaches.
Mechanism: Protein therapeutics or small molecule mimetics activating Tie2 signaling
Drug Pipeline (1 compounds)
1 Approved
Known Drugs:
Faricimab (approved) β€” Neovascular age-related macular degeneration
Structural Data:
PDB (5) βœ“AlphaFold βœ“Cryo-EM β€”
4EPU4JYO4K0V9IVT9IVU
UniProt: E5RFF4

🧬 3D Protein Structure

🧬 ANGPT1 — PDB 2H2L Click to expand interactive 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll

Selectivity & Safety Considerations

ANGPT1 selectivity is advantageous as it specifically targets the Tie2 receptor pathway with minimal known off-targets; however, care must be taken to avoid cross-reactivity with ANGPT2 or other angiopoietin family members. The main selectivity challenge involves achieving Tie2-specific activation while avoiding unintended vascular permeability changes in non-target tissues.

3D Protein Structure

PDB: Open in RCSB AlphaFold model

Interactive 3D viewer powered by RCSB PDB / Mol*. Use mouse to rotate, scroll to zoom.

Clinical Trials (7)

Relevant trials from ClinicalTrials.gov

Active
2
Completed
5
Total Enrollment
429
By Phase
NA: 1 Β· PHASE2: 2 Β· PHASE4: 2 Β· Unknown: 2
Study to Investigate the Efficacy, Safety and Durability of Faricimab in Caucasian Patients With Polypoidal Choroidal Va Recruiting
PHASE4 NCT06709339 n=120
Polypoidal Choroidal Vasculopathy
Interventions: Faricimab Injection [Vabysmo]
Sponsor: Association for Innovation and Biomedical Research on Light | Started: 2025-08-06
Comparing Efficacy of 8-Week and 12-Week Faricimab Initial Follow-Up Treatment Intervals Recruiting
PHASE4 NCT06875245 n=100
Wet Age-related Macular Degeneration
Interventions: Faricimab Injection
Sponsor: Faculty Hospital Kralovske Vinohrady | Started: 2023-03-31
A Study to Investigate Aqueous Humor and Multimodal Imaging Biomarkers in Treatment-NaΓ―ve Participants With Diabetic Mac Completed
PHASE2 NCT04597918 n=99
Diabetic Macular Edema
Interventions: Faricimab
Sponsor: Hoffmann-La Roche | Started: 2020-11-25
Intravitreal Faricimab in Patients With Refractory Macular Edema Completed
PHASE2 NCT07093385 n=43
Age-Related Macular Degeneration
Interventions: Faricimab Injection
Sponsor: University of Baghdad | Started: 2024-09-10
Biological Changes in Fibrovascular Membranes of Patients With Proliferative Diabetic Retinopathy Following Faricimab In Completed
NA NCT07144865 n=8
Proliferative Diabetic Retinopathy
Interventions: conbercept ophthalmic injection （0.5mgοΌ‰, Faricimab
Sponsor: Bojie Hu | Started: 2024-12-01
Single Injection of Faricimab for nAMD With Persisting Fluid Despite Frequent Aflibercept Treatments Completed
Unknown NCT06124677 n=46
Neovascular Age-related Macular Degenera
Interventions: Faricimab
Sponsor: Rigshospitalet, Denmark | Started: 2023-11-01
Switching to Faricimab in Neovascular Age-related Macular Degeneration Resistant to Both Aflibercept and Ranibizumab Completed
Unknown NCT06231121 n=13
Neovascular Age-related Macular Degenera
Interventions: Faricimab
Sponsor: Rigshospitalet, Denmark | Started: 2023-12-01

Linked Hypotheses (0)

No linked hypotheses

Linked Experiments (0)

No linked experiments

Scoring Dimensions

Portfolio 0.66 (25%) Druggability 0.45 (20%) Evidence 0.51 (20%) Safety 0.50 (15%) Competitive 0.40 (10%) Connectivity 0.90 (10%) 0.559 composite

Knowledge Graph (20)

activates (3)

BMP2 β†’ ANGPT1
VEGF β†’ ANGPT1
FGF2 β†’ ANGPT1

associated with (1)

ANGPT1 β†’ neurodegeneration

co discussed (14)

FOXP3 β†’ ANGPT1
TNFA β†’ ANGPT1
PPARGC1A β†’ ANGPT1
PRKAA1 β†’ ANGPT1
NR3C1 β†’ ANGPT1
...and 9 more

interacts with (2)

PDGFRB β†’ ANGPT1
ANGPT1 β†’ PDGFRB

Debate History (0)

No debates yet

← Back to Exchange | Dashboard